Alterity Therapeutics Ltd. · ASX:ATH

Alterity Therapeutics — Shareholder Meeting (November 2026)

12 slides from Alterity Therapeutics's shareholder meeting presentation, Nov 20, 2026

  1. Slide 1: Annual General Meeting 20 November 2026

    Annual General Alterit Meeting 50 Neen 20 November 2026

  2. Slide 2: Forward looking statements

    Forward looking statements ‘This presentation shoud be rea in conjunction with thers actors dsclosed in Atety Therapeutics Limited's mast recent lings with the Australian Securitas Exchange ‘andthe United States Secures and Exchange Commission including the Company/s most recent Annal Report on Form

  3. Slide 3: Redefining Neurodegenerative Disease Therapy

    Redefi 1g Neurodegenerative ease Therapy ATH434: Potential First-in-Class, Disease-Modifying Therapy for Multiple System Atrophy (MSA) Compelling Phase 2 Efficacy on FDA-Endorsed Endpoint ~ Up to 46% slowing of disease progression v. placebo (p<0.05) on FDA-endorsed endpoint’ ~ Favorable safety prof

  4. Slide 4: We delivered on the three objectives we set for 2026

    We delivered on the three objectives we set for 2026 WHat WE DID ‘Two Type C meetings and an End-of-Phase 2 meeting, FDA agreed ‘nia rts the Phased dng wn ates Gea Sat pe ‘confirmatory evidence could support approval. First registration, batch manufactured, 2 _ Deepen engagement across the 9 scienti

  5. Slide 5: Every quarter of FY26 delivered key milestones

    Every quarter of FY26 delivered key milestones QUFY26 Positive topline data from ATH434-202 ‘open-label trial in ‘advanced MSA ED ee evened publication on BioMUSE Novel MRI endpoint ‘ANA Phase 2data presentation EBD 152242 m4 peak revenues independent commercial assessment Bes Alterity Q2 FY26 (Oct-

  6. Slide 6: Our treatment approach: Address underlying pathology

    Our treatment approach: Address underlying pathology Increased Brain Iron in Areas of Pathology Break the Vicious Cycle ‘Multiple System Atrophy (x a — eT a —— relitonig of human rin m Patients = Healthy controls oy. Alterity Key drivers of pathology

  7. Slide 7: Multiple data analyses strengthened the understanding of ATH434 mechanism

    Multiple data analyses strengthened the understanding of ATH434 mechanism and provide a clear path to Phase 3 ~ 46-52% slowing of functional decline on UMSARS Part | across enemres ‘analyses, well above the clinically meaningful threshold = 49% slowing on exploratory outcome of dally function and eu

  8. Slide 8: FDA engagement secured alignment on key elements of the Phase 3 program

    FDA engagement secured alignment on key elements of the Phase 3 program Type C meeting ‘Type C meeting End-of-Phase 2 opy Alterity What the FDA agreed at End-of-Phase 2 Pathway Population Dose and duration Primary endpoint Key secondary endpoints. ‘Statistics and safety Single pivotal trial plus con

  9. Slide 9: New patent extends the life of ATH434

    New patent extends the life of ATH434 NEW U.S. COMPOSITION OF MATTER PATENT 2045 Protection for ATH434 to 2045 = Covers the crystalline mesylate form used in Phase 2 and planned for Phase ~ Includes methods of treating neurological conditions = Composition of matter claims are among the strongest fo

  10. Slide 10: Independent research and physician feedback point to a significant opportunity

    Independent research and physician feedback point to a significant opportunity for ATH434 in MSA Of, of surveyed neurologists “extremely likely" or “very >TO% _ikeiyrto prescribe atHas4 based on its profile US$2.4B Potential worldwide annual peak sales for ATH434 in MSA, if approved Drivers of physi

  11. Slide 11: Positioned for Success

    Positioned for Success REGULATORY MILESTONES + FDA alignment on Phase 3 study design + Type C alignment on clinical pharmacology and non- clinical elements + Type C alignment on Chemistry, Manufacturing & Controls (CMC) PHASE 3 READINESS + Initiated trial start-up activities + Finalize protocol + Cl

  12. Slide 12: Alterity Therapeutics

    ASX: ATH oft. Alterity NASDAQ: ATHE THERAPEUTICS

Alterity Therapeutics — Shareholder Meeting (November 2026) on 6ix